TESARO (TSRO) PT Raised to $100 at Mizuho Ahead of Multiple Catalysts

August 5, 2016 6:33 AM EDT
Get Alerts TSRO Hot Sheet
Price: $149.40 -1.22%

Rating Summary:
    14 Buy, 2 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 11 | Down: 20 | New: 54
Trade TSRO Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Mizuho Securities analyst Eric Criscuolo reiterated a Buy rating and lifted his price target on Tesaro (NASDAQ: TSRO) to $100.00 (from $94.00) ahead of multiple catalysts with drivers in place.

Criscuolo commented, "We're reiterating our Buy and raising our PT to $100. We see a steady stream of potential data catalysts for niraparib over the next year-plus that could add to the excitement following NOVA results. VARUBI is gaining share, with a 1H17 IV launch to address the vast majority of the U.S. market, and an early immuno-oncology pipeline could produce first-in-class assets. Cash utilization is going up but its funding significant product launches. TSRO remains our top Biotech pick."

For an analyst ratings summary and ratings history on Tesaro click here. For more ratings news on Tesaro click here.

Shares of Tesaro closed at $89.45 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change, FDA

Add Your Comment